By 2024 fluoroquinolones will become the largest drug segment to treat bacterial conjunctivitis, a common eye infection, according to a recent post on Eurowire. Value of the market will be $439.8 million. There are about 5 million acute bacterial conjunctivitis cases reported in the U.S. each year and the incidence is increasing. Although other drugs can be given for this condition, fluoroquinolones dominate the market. Little is known about the side effects or damage done by fluoroquinolones in eye treatment. Reports of eye injury suspected to be caused by these drugs abound on the internet and in patient advocacy groups.